Pharmaceutical Training

From Compliance to Resilience: How Companies Can Build Quality Systems That Withstand Disruption

The NSF Pharma Biotech Conference returns in 2026 for what promises to be the most ambitious and forward-looking event in the conference series to date. Building on the success of previous events held between 2023 and 2025, this year’s conference will bring together senior leaders and industry experts from across the pharmaceutical and biotechnology sectors to explore one of the defining challenges facing the industry today: how organisations can move beyond compliance and build resilient quality systems capable of withstanding disruption, uncertainty, and accelerating change.

Over the past three years, the NSF conference series has established itself as a respected forum for high-level discussion on pharmaceutical quality, regulatory change, supply chain resilience, AI and digital transformation, medicines shortages, contamination control strategies, and leadership within the pharmaceutical quality system. Previous conferences have featured speakers from organisations including  The European Medicines Agency (EMA), MHRA, major pharmaceutical manufacturers, industry associations, and NSF subject matter experts. Discussions have explored topics ranging from AI in pharmaceutical manufacturing and drug development to medicines shortages, contamination control strategies, advanced manufacturing technologies, and quality management maturity.

The 2026 conference will build on those foundations while responding to the rapidly evolving realities facing the global life sciences industry. Pharmaceutical companies today are operating in an environment shaped by geopolitical uncertainty, changing global trade dynamics, supply chain pressures, evolving regulatory expectations, digital disruption, workforce challenges, and increasing scrutiny around product quality and patient safety. Organisations are being asked not only to maintain compliance, but to demonstrate agility, resilience, and operational maturity in the face of continuous disruption.

Against this backdrop, the theme for 2026 — From Compliance to Resilience: How Companies Can Build Quality Systems That Withstand Disruption, will focus on how pharmaceutical and biotech organisations can strengthen their quality systems, leadership approaches, operational models, and organisational cultures to thrive in an increasingly complex environment.

This year’s conference will feature speakers from large global pharmaceutical companies, innovative biotechnology organisations, CDMOs, regulatory experts, and senior leaders working at the forefront of pharmaceutical quality and operational excellence. The programme is being designed specifically for senior and mid-level professionals involved in quality, manufacturing, supply chain, regulatory affairs, operational excellence, and leadership roles across the life sciences sector.

The conference will provide a full day of in-depth presentations, practical case studies, panel discussions, and networking opportunities. Unlike many industry events that focus purely on theory or high-level commentary, the NSF Pharma Biotech Conference has built its reputation on delivering practical, experience-led insights from professionals actively dealing with the challenges facing the industry today.

Join us in November for a full day of insight, collaboration, and industry discussion as we explore how pharmaceutical and biotech organisations can move from compliance to resilience, and build quality systems capable of withstanding disruption in an increasingly complex world.